The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC).
D. E. Rathkopf
No relevant relationships to disclose
D. C. Danila
No relevant relationships to disclose
S. F. Slovin
No relevant relationships to disclose
M. J. Morris
No relevant relationships to disclose
J. E. Steinbrecher
No relevant relationships to disclose
Y. Chen
No relevant relationships to disclose
M. Fleisher
No relevant relationships to disclose
S. M. Larson
No relevant relationships to disclose
C. L. Sawyers
Consultant or Advisory Role - Aragon Pharmaceuticals (U)
Stock Ownership - Aragon Pharmaceuticals
H. I. Scher
Consultant or Advisory Role - Aragon Pharmaceuticals (U)